Patents by Inventor Thomas A. Werfel

Thomas A. Werfel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220241317
    Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.
    Type: Application
    Filed: September 14, 2021
    Publication date: August 4, 2022
    Inventors: Craig L. Duvall, Samantha M. Sarett, Thomas A. Werfel
  • Patent number: 11147827
    Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: October 19, 2021
    Assignee: Vanderbilt University
    Inventors: Craig L. Duvall, Samantha M. Sarett, Thomas A. Werfel
  • Patent number: 10105455
    Abstract: Disclosed are compositions that comprise a cyclooxygenase-2-selective therapeutic and/or diagnostic agent having a therapeutic and/or diagnostic agent conjugated to a NSAID drug; and a ROS-responsive nanoparticle. Methods of making and using these compositions for drug encapsulation and delivery are also disclosed.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: October 23, 2018
    Assignee: Vanderbilt University
    Inventors: Craig L. Duvall, Lawrence J. Marnett, Jashim Uddin, Thomas A. Werfel, Mukesh Gupta, Brenda C. Crews
  • Publication number: 20180064749
    Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.
    Type: Application
    Filed: August 7, 2017
    Publication date: March 8, 2018
    Inventors: Craig L. Duvall, Samantha M. Sarett, Thomas A. Werfel
  • Publication number: 20170007723
    Abstract: Disclosed are compositions that comprise a cyclooxygenase-2-selective therapeutic and/or diagnostic agent having a therapeutic and/or diagnostic agent conjugated to a NSAID drug; and a ROS-responsive nanoparticle. Methods of making and using these compositions for drug encapsulation and delivery are also disclosed.
    Type: Application
    Filed: July 11, 2016
    Publication date: January 12, 2017
    Inventors: Craig L. Duvall, Lawrence J. Marnett, Jashim Uddin, Thomas A. Werfel, Mukesh Gupta, Brenda C. Crews
  • Publication number: 20120171238
    Abstract: The invention discloses the use of a protein with an amino acid sequence according to SEQ. ID. NO. 1 or a naturally occurring fragment or variant thereof for identifying infections with S. aureus in a human sample. More specifically, IgE molecules specific for SEQ. ID. NO. 1 are detected in the sample of the patient. Many atopic dermatitis patients have IgE specific for SEQ. ID. NO. 1.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 5, 2012
    Applicant: BIOMAY AG
    Inventors: Rudolf Valenta, Kavita Reginald, Kerstin Westritschnig, Birgit Linhart, Angelika Stöcklinger, Josef Thalhamer, Alexander M. Hirschi, Thomas Werfel, Elli Greisenegger, Tamara Kopp